http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 28 May 2026 07:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Enanta+Pharmaceuticals+to+Present+at+the+Jefferies+Global+Healthcare+Conference/26560921.html <p> WATERTOWN, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.enanta.com%2F&amp;esheet=54541740&amp;newsitemid=20260528371311&amp;lan=en-US&amp;anchor=Enanta+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=8d7bfe0ed1c1a7864d2b42de4272b463" shape="rect">Enanta Pharmaceuticals, Inc.</a> (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 4, 2026 at 11:40 a.m. ET in New York, NY. </p><p> A live webcast of the event will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at <a http://www.streetinsider.com/Press+Releases/Enanta+Pharmaceuticals+to+Present+at+the+Jefferies+Global+Healthcare+Conference/26560921.html Thu, 28 May 2026 07:00:00 -0400 ENTA O.00184235 http://www.streetinsider.com/Press+Releases/Enanta+Pharmaceuticals+to+Present+at+the+Jefferies+Global+Healthcare+Conference/26560921.html <p> WATERTOWN, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.enanta.com%2F&amp;esheet=54541740&amp;newsitemid=20260528371311&amp;lan=en-US&amp;anchor=Enanta+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=8d7bfe0ed1c1a7864d2b42de4272b463" shape="rect">Enanta Pharmaceuticals, Inc.</a> (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 4, 2026 at 11:40 a.m. ET in New York, NY. </p><p> A live webcast of the event will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at <a http://www.streetinsider.com/Press+Releases/Enanta+Pharmaceuticals+to+Present+at+the+Jefferies+Global+Healthcare+Conference/26560921.html Thu, 28 May 2026 07:00:00 -0400 ENTA O.00184235 http://www.streetinsider.com/Business+Wire/Enanta+Pharmaceuticals+to+Present+at+the+Jefferies+Global+Healthcare+Conference/26560921.html <p> WATERTOWN, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.enanta.com%2F&amp;esheet=54541740&amp;newsitemid=20260528371311&amp;lan=en-US&amp;anchor=Enanta+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=8d7bfe0ed1c1a7864d2b42de4272b463" shape="rect">Enanta Pharmaceuticals, Inc.</a> (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 4, 2026 at 11:40 a.m. ET in New York, NY. </p><p> A live webcast of the event will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at <a http://www.streetinsider.com/Business+Wire/Enanta+Pharmaceuticals+to+Present+at+the+Jefferies+Global+Healthcare+Conference/26560921.html Thu, 28 May 2026 07:00:00 -0400 ENTA O.00184235 http://www.streetinsider.com/Business+Wire/Enanta+Pharmaceuticals+to+Present+at+the+Jefferies+Global+Healthcare+Conference/26560921.html <p> WATERTOWN, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.enanta.com%2F&amp;esheet=54541740&amp;newsitemid=20260528371311&amp;lan=en-US&amp;anchor=Enanta+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=8d7bfe0ed1c1a7864d2b42de4272b463" shape="rect">Enanta Pharmaceuticals, Inc.</a> (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 4, 2026 at 11:40 a.m. ET in New York, NY. </p><p> A live webcast of the event will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at <a http://www.streetinsider.com/Business+Wire/Enanta+Pharmaceuticals+to+Present+at+the+Jefferies+Global+Healthcare+Conference/26560921.html Thu, 28 May 2026 07:00:00 -0400 ENTA O.00184235 http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++ENANTA+PHARMACEUTICALS+++++++++++++++/26481693.html si-local-file:///var/storage/secattach/20260513/26481693.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++ENANTA+PHARMACEUTICALS+++++++++++++++/26481693.html Wed, 13 May 2026 07:26:00 -0400 ENTA O.00184235 http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++ENANTA+PHARMACEUTICALS+++++++++++++++/26481693.html si-local-file:///var/storage/secattach/20260513/26481693.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++ENANTA+PHARMACEUTICALS+++++++++++++++/26481693.html Wed, 13 May 2026 07:26:00 -0400 ENTA O.00184235 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++ENANTA+PHARMACEUTICALS++++For%3A+Mar+31/26481463.html si-local-file:///var/storage/secattach/20260513/26481463.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++ENANTA+PHARMACEUTICALS++++For%3A+Mar+31/26481463.html Wed, 13 May 2026 07:01:00 -0400 ENTA O.00184235 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++ENANTA+PHARMACEUTICALS++++For%3A+Mar+31/26481463.html si-local-file:///var/storage/secattach/20260513/26481463.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++ENANTA+PHARMACEUTICALS++++For%3A+Mar+31/26481463.html Wed, 13 May 2026 07:01:00 -0400 ENTA O.00184235 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ENANTA+PHARMACEUTICALS++++For%3A+May+11/26468946.html si-local-file:///var/storage/secattach/20260511/26468946.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ENANTA+PHARMACEUTICALS++++For%3A+May+11/26468946.html Mon, 11 May 2026 16:06:00 -0400 ENTA O.00184235 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ENANTA+PHARMACEUTICALS++++For%3A+May+11/26468946.html si-local-file:///var/storage/secattach/20260511/26468946.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ENANTA+PHARMACEUTICALS++++For%3A+May+11/26468946.html Mon, 11 May 2026 16:06:00 -0400 ENTA O.00184235 http://www.streetinsider.com/Earnings/Enanta+Pharma+%28ENTA%29+Tops+Q2+EPS+by+12c/26468702.html <p>Enanta Pharma (NASDAQ: ENTA) reported Q2 EPS of ($0.45), $0.12 better than the analyst estimate of ($0.57). Revenue for the quarter came in at $17.2 million versus the consensus estimate of $16.75 million.</p> <p>For earnings history and earnings-related data on Enanta Pharma (ENTA) <a href="http://www.streetinsider.com/ec_earnings.php?q=ENTA">click here</a>.</p> http://www.streetinsider.com/Earnings/Enanta+Pharma+%28ENTA%29+Tops+Q2+EPS+by+12c/26468702.html Mon, 11 May 2026 16:01:45 -0400 ENTA http://www.streetinsider.com/Press+Releases/Enanta+Pharmaceuticals+Reports+Financial+Results+for+its+Fiscal+Second+Quarter+Ended+March+31%2C+2026/26468673.html <ul class="bwlistdisc"> <li> <i>Dosing Initiated in a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Chronic Urticaria; On Track to Report Topline Data in 4Q 2026</i> </li> <li> <i>Conducting Enabling Activities for a Pivotal Study of Zelicapavir in High-Risk Adults with Respiratory Syncytial Virus (RSV)</i> </li> <li> <i>On Track to File an IND for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor Development Candidate and to Select an MRGPRX2 Development Candidate, in 2H 2026</i> </li> <li> <i>Cash and Marketable Securities Totaling $227 Million at March 31, 2026, as well as Continuing Retained Royalties, with Cash Runway Expected to Fund Operations into Fiscal 2029</i> </li> </ul> <p> http://www.streetinsider.com/Press+Releases/Enanta+Pharmaceuticals+Reports+Financial+Results+for+its+Fiscal+Second+Quarter+Ended+March+31%2C+2026/26468673.html Mon, 11 May 2026 16:01:00 -0400 A.06822034 A.60012014 ENTA O.00184235 O.00638181 O.20026344 http://www.streetinsider.com/Press+Releases/Enanta+Pharmaceuticals+Reports+Financial+Results+for+its+Fiscal+Second+Quarter+Ended+March+31%2C+2026/26468673.html <ul class="bwlistdisc"> <li> <i>Dosing Initiated in a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Chronic Urticaria; On Track to Report Topline Data in 4Q 2026</i> </li> <li> <i>Conducting Enabling Activities for a Pivotal Study of Zelicapavir in High-Risk Adults with Respiratory Syncytial Virus (RSV)</i> </li> <li> <i>On Track to File an IND for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor Development Candidate and to Select an MRGPRX2 Development Candidate, in 2H 2026</i> </li> <li> <i>Cash and Marketable Securities Totaling $227 Million at March 31, 2026, as well as Continuing Retained Royalties, with Cash Runway Expected to Fund Operations into Fiscal 2029</i> </li> </ul> <p> http://www.streetinsider.com/Press+Releases/Enanta+Pharmaceuticals+Reports+Financial+Results+for+its+Fiscal+Second+Quarter+Ended+March+31%2C+2026/26468673.html Mon, 11 May 2026 16:01:00 -0400 A.06822034 A.60012014 ENTA O.00184235 O.00638181 O.20026344 http://www.streetinsider.com/Press+Releases/Enanta+Pharmaceuticals+Reports+Financial+Results+for+its+Fiscal+Second+Quarter+Ended+March+31%2C+2026/26468673.html <ul class="bwlistdisc"> <li> <i>Dosing Initiated in a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Chronic Urticaria; On Track to Report Topline Data in 4Q 2026</i> </li> <li> <i>Conducting Enabling Activities for a Pivotal Study of Zelicapavir in High-Risk Adults with Respiratory Syncytial Virus (RSV)</i> </li> <li> <i>On Track to File an IND for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor Development Candidate and to Select an MRGPRX2 Development Candidate, in 2H 2026</i> </li> <li> <i>Cash and Marketable Securities Totaling $227 Million at March 31, 2026, as well as Continuing Retained Royalties, with Cash Runway Expected to Fund Operations into Fiscal 2029</i> </li> </ul> <p> http://www.streetinsider.com/Press+Releases/Enanta+Pharmaceuticals+Reports+Financial+Results+for+its+Fiscal+Second+Quarter+Ended+March+31%2C+2026/26468673.html Mon, 11 May 2026 16:01:00 -0400 A.06822034 A.60012014 ENTA O.00184235 O.00638181 O.20026344 http://www.streetinsider.com/Press+Releases/Enanta+Pharmaceuticals+Reports+Financial+Results+for+its+Fiscal+Second+Quarter+Ended+March+31%2C+2026/26468673.html <ul class="bwlistdisc"> <li> <i>Dosing Initiated in a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Chronic Urticaria; On Track to Report Topline Data in 4Q 2026</i> </li> <li> <i>Conducting Enabling Activities for a Pivotal Study of Zelicapavir in High-Risk Adults with Respiratory Syncytial Virus (RSV)</i> </li> <li> <i>On Track to File an IND for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor Development Candidate and to Select an MRGPRX2 Development Candidate, in 2H 2026</i> </li> <li> <i>Cash and Marketable Securities Totaling $227 Million at March 31, 2026, as well as Continuing Retained Royalties, with Cash Runway Expected to Fund Operations into Fiscal 2029</i> </li> </ul> <p> http://www.streetinsider.com/Press+Releases/Enanta+Pharmaceuticals+Reports+Financial+Results+for+its+Fiscal+Second+Quarter+Ended+March+31%2C+2026/26468673.html Mon, 11 May 2026 16:01:00 -0400 A.06822034 A.60012014 ENTA O.00184235 O.00638181 O.20026344 http://www.streetinsider.com/Press+Releases/Enanta+Pharmaceuticals+Reports+Financial+Results+for+its+Fiscal+Second+Quarter+Ended+March+31%2C+2026/26468673.html <ul class="bwlistdisc"> <li> <i>Dosing Initiated in a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Chronic Urticaria; On Track to Report Topline Data in 4Q 2026</i> </li> <li> <i>Conducting Enabling Activities for a Pivotal Study of Zelicapavir in High-Risk Adults with Respiratory Syncytial Virus (RSV)</i> </li> <li> <i>On Track to File an IND for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor Development Candidate and to Select an MRGPRX2 Development Candidate, in 2H 2026</i> </li> <li> <i>Cash and Marketable Securities Totaling $227 Million at March 31, 2026, as well as Continuing Retained Royalties, with Cash Runway Expected to Fund Operations into Fiscal 2029</i> </li> </ul> <p> http://www.streetinsider.com/Press+Releases/Enanta+Pharmaceuticals+Reports+Financial+Results+for+its+Fiscal+Second+Quarter+Ended+March+31%2C+2026/26468673.html Mon, 11 May 2026 16:01:00 -0400 A.06822034 A.60012014 ENTA O.00184235 O.00638181 O.20026344 http://www.streetinsider.com/Press+Releases/Enanta+Pharmaceuticals+Reports+Financial+Results+for+its+Fiscal+Second+Quarter+Ended+March+31%2C+2026/26468673.html <ul class="bwlistdisc"> <li> <i>Dosing Initiated in a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Chronic Urticaria; On Track to Report Topline Data in 4Q 2026</i> </li> <li> <i>Conducting Enabling Activities for a Pivotal Study of Zelicapavir in High-Risk Adults with Respiratory Syncytial Virus (RSV)</i> </li> <li> <i>On Track to File an IND for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor Development Candidate and to Select an MRGPRX2 Development Candidate, in 2H 2026</i> </li> <li> <i>Cash and Marketable Securities Totaling $227 Million at March 31, 2026, as well as Continuing Retained Royalties, with Cash Runway Expected to Fund Operations into Fiscal 2029</i> </li> </ul> <p> http://www.streetinsider.com/Press+Releases/Enanta+Pharmaceuticals+Reports+Financial+Results+for+its+Fiscal+Second+Quarter+Ended+March+31%2C+2026/26468673.html Mon, 11 May 2026 16:01:00 -0400 A.06822034 A.60012014 ENTA O.00184235 O.00638181 O.20026344 http://www.streetinsider.com/Business+Wire/Enanta+Pharmaceuticals+Reports+Financial+Results+for+its+Fiscal+Second+Quarter+Ended+March+31%2C+2026/26468673.html <ul class="bwlistdisc"> <li> <i>Dosing Initiated in a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Chronic Urticaria; On Track to Report Topline Data in 4Q 2026</i> </li> <li> <i>Conducting Enabling Activities for a Pivotal Study of Zelicapavir in High-Risk Adults with Respiratory Syncytial Virus (RSV)</i> </li> <li> <i>On Track to File an IND for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor Development Candidate and to Select an MRGPRX2 Development Candidate, in 2H 2026</i> </li> <li> <i>Cash and Marketable Securities Totaling $227 Million at March 31, 2026, as well as Continuing Retained Royalties, with Cash Runway Expected to Fund Operations into Fiscal 2029</i> </li> </ul> <p> http://www.streetinsider.com/Business+Wire/Enanta+Pharmaceuticals+Reports+Financial+Results+for+its+Fiscal+Second+Quarter+Ended+March+31%2C+2026/26468673.html Mon, 11 May 2026 16:01:00 -0400 A.06822034 A.60012014 ENTA O.00184235 O.00638181 O.20026344 http://www.streetinsider.com/Business+Wire/Enanta+Pharmaceuticals+Reports+Financial+Results+for+its+Fiscal+Second+Quarter+Ended+March+31%2C+2026/26468673.html <ul class="bwlistdisc"> <li> <i>Dosing Initiated in a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Chronic Urticaria; On Track to Report Topline Data in 4Q 2026</i> </li> <li> <i>Conducting Enabling Activities for a Pivotal Study of Zelicapavir in High-Risk Adults with Respiratory Syncytial Virus (RSV)</i> </li> <li> <i>On Track to File an IND for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor Development Candidate and to Select an MRGPRX2 Development Candidate, in 2H 2026</i> </li> <li> <i>Cash and Marketable Securities Totaling $227 Million at March 31, 2026, as well as Continuing Retained Royalties, with Cash Runway Expected to Fund Operations into Fiscal 2029</i> </li> </ul> <p> http://www.streetinsider.com/Business+Wire/Enanta+Pharmaceuticals+Reports+Financial+Results+for+its+Fiscal+Second+Quarter+Ended+March+31%2C+2026/26468673.html Mon, 11 May 2026 16:01:00 -0400 A.06822034 A.60012014 ENTA O.00184235 O.00638181 O.20026344 http://www.streetinsider.com/Business+Wire/Enanta+Pharmaceuticals+Reports+Financial+Results+for+its+Fiscal+Second+Quarter+Ended+March+31%2C+2026/26468673.html <ul class="bwlistdisc"> <li> <i>Dosing Initiated in a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Chronic Urticaria; On Track to Report Topline Data in 4Q 2026</i> </li> <li> <i>Conducting Enabling Activities for a Pivotal Study of Zelicapavir in High-Risk Adults with Respiratory Syncytial Virus (RSV)</i> </li> <li> <i>On Track to File an IND for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor Development Candidate and to Select an MRGPRX2 Development Candidate, in 2H 2026</i> </li> <li> <i>Cash and Marketable Securities Totaling $227 Million at March 31, 2026, as well as Continuing Retained Royalties, with Cash Runway Expected to Fund Operations into Fiscal 2029</i> </li> </ul> <p> http://www.streetinsider.com/Business+Wire/Enanta+Pharmaceuticals+Reports+Financial+Results+for+its+Fiscal+Second+Quarter+Ended+March+31%2C+2026/26468673.html Mon, 11 May 2026 16:01:00 -0400 A.06822034 A.60012014 ENTA O.00184235 O.00638181 O.20026344 http://www.streetinsider.com/Business+Wire/Enanta+Pharmaceuticals+Reports+Financial+Results+for+its+Fiscal+Second+Quarter+Ended+March+31%2C+2026/26468673.html <ul class="bwlistdisc"> <li> <i>Dosing Initiated in a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Chronic Urticaria; On Track to Report Topline Data in 4Q 2026</i> </li> <li> <i>Conducting Enabling Activities for a Pivotal Study of Zelicapavir in High-Risk Adults with Respiratory Syncytial Virus (RSV)</i> </li> <li> <i>On Track to File an IND for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor Development Candidate and to Select an MRGPRX2 Development Candidate, in 2H 2026</i> </li> <li> <i>Cash and Marketable Securities Totaling $227 Million at March 31, 2026, as well as Continuing Retained Royalties, with Cash Runway Expected to Fund Operations into Fiscal 2029</i> </li> </ul> <p> http://www.streetinsider.com/Business+Wire/Enanta+Pharmaceuticals+Reports+Financial+Results+for+its+Fiscal+Second+Quarter+Ended+March+31%2C+2026/26468673.html Mon, 11 May 2026 16:01:00 -0400 A.06822034 A.60012014 ENTA O.00184235 O.00638181 O.20026344 http://www.streetinsider.com/Business+Wire/Enanta+Pharmaceuticals+Reports+Financial+Results+for+its+Fiscal+Second+Quarter+Ended+March+31%2C+2026/26468673.html <ul class="bwlistdisc"> <li> <i>Dosing Initiated in a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Chronic Urticaria; On Track to Report Topline Data in 4Q 2026</i> </li> <li> <i>Conducting Enabling Activities for a Pivotal Study of Zelicapavir in High-Risk Adults with Respiratory Syncytial Virus (RSV)</i> </li> <li> <i>On Track to File an IND for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor Development Candidate and to Select an MRGPRX2 Development Candidate, in 2H 2026</i> </li> <li> <i>Cash and Marketable Securities Totaling $227 Million at March 31, 2026, as well as Continuing Retained Royalties, with Cash Runway Expected to Fund Operations into Fiscal 2029</i> </li> </ul> <p> http://www.streetinsider.com/Business+Wire/Enanta+Pharmaceuticals+Reports+Financial+Results+for+its+Fiscal+Second+Quarter+Ended+March+31%2C+2026/26468673.html Mon, 11 May 2026 16:01:00 -0400 A.06822034 A.60012014 ENTA O.00184235 O.00638181 O.20026344 http://www.streetinsider.com/Business+Wire/Enanta+Pharmaceuticals+Reports+Financial+Results+for+its+Fiscal+Second+Quarter+Ended+March+31%2C+2026/26468673.html <ul class="bwlistdisc"> <li> <i>Dosing Initiated in a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Chronic Urticaria; On Track to Report Topline Data in 4Q 2026</i> </li> <li> <i>Conducting Enabling Activities for a Pivotal Study of Zelicapavir in High-Risk Adults with Respiratory Syncytial Virus (RSV)</i> </li> <li> <i>On Track to File an IND for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor Development Candidate and to Select an MRGPRX2 Development Candidate, in 2H 2026</i> </li> <li> <i>Cash and Marketable Securities Totaling $227 Million at March 31, 2026, as well as Continuing Retained Royalties, with Cash Runway Expected to Fund Operations into Fiscal 2029</i> </li> </ul> <p> http://www.streetinsider.com/Business+Wire/Enanta+Pharmaceuticals+Reports+Financial+Results+for+its+Fiscal+Second+Quarter+Ended+March+31%2C+2026/26468673.html Mon, 11 May 2026 16:01:00 -0400 A.06822034 A.60012014 ENTA O.00184235 O.00638181 O.20026344 http://www.streetinsider.com/Press+Releases/Enanta+Pharmaceuticals+to+Present+Data+for+its+Respiratory+Syncytial+Virus+and+STAT6+Inhibitor+Programs+at+the+American+Thoracic+Society+International+Conference+2026/26420715.html <p> WATERTOWN, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.enanta.com%2F&amp;esheet=54526369&amp;newsitemid=20260504237451&amp;lan=en-US&amp;anchor=Enanta+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=7af31dc036339a40a3a30155dd66f395" shape="rect">Enanta Pharmaceuticals, Inc.</a> (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that the Company will have an oral presentation highlighting zelicapavir and two posters with data on EPS-3903, a novel, potent and selective oral STAT6 inhibitor, at the American Thoracic Society (ATS)<b> </b>International Conference 2026<b> </b>being held May 15-20, 2026 in Orlando, Florida. </p><p> Details of the presentations are as follows: </p><p> <b>Title: </b>Zelicapavir Reduces Symptom Duration and Hospitalization in a Randomized, Double-Blind, Placebo-Controlled, International, Phase 2 Trial <br /><b>Abstract Number: </b>12336 <br /><b>Session C96: http://www.streetinsider.com/Press+Releases/Enanta+Pharmaceuticals+to+Present+Data+for+its+Respiratory+Syncytial+Virus+and+STAT6+Inhibitor+Programs+at+the+American+Thoracic+Society+International+Conference+2026/26420715.html Mon, 04 May 2026 07:00:00 -0400 A.03506689 A.60012014 ENTA O.00184235 O.00638181 O.19059164 http://www.streetinsider.com/Press+Releases/Enanta+Pharmaceuticals+to+Present+Data+for+its+Respiratory+Syncytial+Virus+and+STAT6+Inhibitor+Programs+at+the+American+Thoracic+Society+International+Conference+2026/26420715.html <p> WATERTOWN, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.enanta.com%2F&amp;esheet=54526369&amp;newsitemid=20260504237451&amp;lan=en-US&amp;anchor=Enanta+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=7af31dc036339a40a3a30155dd66f395" shape="rect">Enanta Pharmaceuticals, Inc.</a> (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that the Company will have an oral presentation highlighting zelicapavir and two posters with data on EPS-3903, a novel, potent and selective oral STAT6 inhibitor, at the American Thoracic Society (ATS)<b> </b>International Conference 2026<b> </b>being held May 15-20, 2026 in Orlando, Florida. </p><p> Details of the presentations are as follows: </p><p> <b>Title: </b>Zelicapavir Reduces Symptom Duration and Hospitalization in a Randomized, Double-Blind, Placebo-Controlled, International, Phase 2 Trial <br /><b>Abstract Number: </b>12336 <br /><b>Session C96: http://www.streetinsider.com/Press+Releases/Enanta+Pharmaceuticals+to+Present+Data+for+its+Respiratory+Syncytial+Virus+and+STAT6+Inhibitor+Programs+at+the+American+Thoracic+Society+International+Conference+2026/26420715.html Mon, 04 May 2026 07:00:00 -0400 A.03506689 A.60012014 ENTA O.00184235 O.00638181 O.19059164